Table 1. Characteristics of Included Studies.
| Control Group Method | Included Trials | Primary Disease | Diagnosis Criteria of AR | Test Measures of AR | Sample (male/ female) | Age (range/mean) | Interventions | Outcomes(* P<0.05, #P<0.01) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Intervention | Control | (year) | Intervention | Control | ||||||
| C:Aspirin100mg/d | Song SJ 2008[20] | Coronary heart disease | AA# and ADP# | Unclear | I1:24 (7/17); | 23(6/17) | I1:65.46±8.08; | I1:Tongxinluo capsule,3pieces,tid+aspirin,100mg/d,4 weeks; | Aspirin,100mg/d,4 weeks | ①②③*⑧* |
| I2:4(7/16) | I2:6.17±7.94; | I2:clopidogrel,75mg/d+aspirin,100mg/d,4 weeks | ||||||||
| C:65.23±7.25 | ||||||||||
| Zhang JL 2010[24] | Cerebral infarction | ADP† | Light or optical transmission | I1:21; | 20 | I1:Tongxinluo capsule,4pieces,tid+aspirin,100mg/d,1 month; | Aspirin,100mg/d,1 month | ①* ③* | ||
| I2:19 | I2:cilostazol,100md/d+aspirin,100mg/d,1 month | |||||||||
| Yin CH 2010[23] | Coronary heart disease | ADP§ and COL | Electrical impedance | I1:30(18/12); | 29(17/12) | I1:43-82/66.55±10.82; | I1:Tongxinluo capsule,3pieces,tid+aspirin,100mg/d,1 month; | Aspirin,100mg/d,1 month | ①* ④*⑮⑰ | |
| C:Aspirin 100mg/d | I2:30(19/11) | I2:46-84/66.69±10.56; | I2:Tongxinluo capsule,3 pieces,tid,1 month | |||||||
| C:44-82/66.93±10.75 | ||||||||||
| Chai ZQ 2008[21] | AA# and ADP# | Light or optical transmission | I1:10(3/7); | 10(3/7) | I1:67.40±14.70; | I1:Compound danshen dripping pill,270mg,tid+aspirin,100mg/d,2 weeks; | Asprin,100mg/d,2 weeks | ①*②* | ||
| I2:10(4/6) | I2:12.31±17.61; | I2:Compound danshen dripping pill,270mg,tid,2 weeks | ||||||||
| C:67.70±12.79 | ||||||||||
| C:Aspirin 100mg/d | Guo HY 2012[30] | ADP# | Light or optical transmission | 50 | 53 | Compound danshen dripping pill,270mg,tid+aspirin,100mg/d,1 month | Aspirin,100mg/d,1 month | ①#⑬*⑭*⑰ | ||
| Zhang X 2013[33] | Coronary heart disease | AA# and ADP# | Light or optical transmission | 20(10/10) | 19(10/9) | I:55.7±6.8; | Compound danshen dripping pill,270mg,tid+aspirin,100mg/d,1 month | Aspirin,100mg/d,1 month | ①#②⑨⑮⑯ | |
| C:57.7±8.2 | ||||||||||
| Wu TH 2012[28] | AA# and ADP# | Light or optical transmission | 30 | 30 | 35-80(total) | Xufuzuyu Decoction,1dose/d+aspirin,100mg/d,4 weeks | Aspirin,100mg/d,4 weeks | ①*②* | ||
| Liu YJ 2013[31] | Cerebral infarction | AA# and ADP# | Light or optical transmission | I1:50; | 42 | 75.19±10.47(total) | I1:Sanqi Tongshu Capsule,200mg,tid+aspirin,100mg/d,1 month; | Aspirin,100mg/d,1 month | ①*②*③*⑩* | |
| C:Aspirin 100mg/d | I2:48 | I2:cilostazol,100md/d+aspirin,100mg/d,1 month | ||||||||
| Huang HM 2014[36] | Cerebral infarction | AA# and ADP# | Unclear | 49(29/20) | 45(27/18) | I:68.7±6.5; | Naoshuantong capsule,1.2,tid+aspirin,100mg/d,12 weeks | Aspirin,100mg/d,12 weeks | ①*②*⑪*⑫*⑬* | |
| C:68.5±6.3 | ||||||||||
| Liu DF 2015[37] | Coronary heart disease | AA# and ADP# | Light or optical transmission | I1:20(11/9); | 20(9/11) | 44-78(total) | I1:Huxin capsule,2 pieces,tid,21 days; | Aspirin,100mg/d,21 days | ①*②*⑮ | |
| I2:20(8/12) | I2:Huxin capsule,2 pieces,tid+aspirin,100mg/d,21 days | |||||||||
| C:Aspirin 200mg/d | Chen G 2013[32] | Coronary heart disease | AA# and ADP# | Light or optical transmission | I1:20(11/9); | 18(10/8) | I1:64.9±8.6; | I1:Xueshuanxinmaining capsule,4 pieces,tid+aspirin,100mg/d,4 weeks; | Aspirin,200mg/d,4 weeks | ①*②*⑮ |
| I2:20(11/9) | I2:6.4.9±8.6; | I2:Xueshuanxinmaining capsule,4 pieces,tid,4 weeks | ||||||||
| C:65.7±7.8 | ||||||||||
| C:Aspirin 300mg/d | Su WJ 2012[27] | AA§ and ADP$ | Light or optical transmission | 30(15/15) | 30(13/17) | I:43-70/62; | Diaoxinxuekang capsule,1.6g,tid,4 weeks | Aspirin,300mg/d,4 weeks | ①*②*③⑤* ⑦*⑮# ⑰ | |
| C:41-70/61.2 | ||||||||||
| Dipyridamole 150mg/d+aspirin 100mg/d | Liu HQ 2008[22] | Cerebral infarction | ADP† | Unclear | 40(21/19) | 40(23/17) | I:38–72; | Zuyu Tongmai Capsule,2pieces,tid+aspirin,100mg/d,1 month | Dipyridamole,150mg/d+aspirin,100mg/d,1 month | ①# |
| C:41–75 | ||||||||||
| Liu QK 2010[25] | Cerebral infarction | AA# and ADP# | Light or optical transmission | 36(21/15) | 36(18/18) | I:46-78/65; | I1:Gingko biloba tablet,2pieces,tid+aspirin,100mg/d,1 month | Dipyridamole,150mg/d+aspirin,100mg/d,1 month | ①#②#⑦*⑮# ⑰ | |
| C:49-78/67 | ||||||||||
| Ma JX 2012[29] | Cerebral infarction | AA# and ADP# | Unclear | 40(23/17) | 40(21/19) | I:43-76/63; | Sodium ferulate tablets,100mg,tid+aspirin,100mg/d,4 weeks | Dipyridamole,150mg/d+aspirin,100mg/d,4 weeks | ①*②*③* | |
| C:45-78/65 | ||||||||||
| Tu XP 2013[35] | Cerebral infarction | AA§ and ADP† | Light or optical transmission | 50(29/21) | 50(26/24) | I:48-71/61.98±7.92; | Compound danshen dripping pill,270mg,tid+aspirin,100mg/d,1 month | Dipyridamole,150mg/d+aspirin,100mg/d,1 month | ①*②*⑬* ⑮* | |
| C:49-70/61.55±8.12 | ||||||||||
| Clopidogrel, 75mg/d+aspirin,100mg/d | Wang J 2012[26] | Coronary heart disease | AA† and ADP# | Thrombelast-ogram | 90(50/40) | 90(61/29) | I:62.4±13.1; | Puerarin injection,200mg/d+clopidogrel, 75mg/d,7 days | Clopidogrel, 75mg/d+aspirin,100mg/d,7 days | ①②#⑥* |
| C:65.1±17.0 | ||||||||||
| Zhang L 2013[34] | Cerebral infarction | AA§ and ADP¶ | Light or optical transmission | 42(24/18) | 42(21/21) | I:44-86/52±13; | Buyang Huanwu Decoction,1 dose/d+aspirin,100mg/d,90 days | Clopidogrel, 75mg/d+aspirin,100mg/d,90 days | ①②⑬⑰ | |
| C:48-82/53±11 | ||||||||||
Diagnosis Criteria of AR: AA#: 0.5mmol/L arachidonic acid induced PAR≥20%; ADP#: 10μmol/L adenosine diphosphate induced PAR≥70%; ADP†: 10mmol/L adenosine diphosphate induced PAR≥70%; ADP§: 10μg/mL adenosine diphosphate induced PAR≥13ohm; COL: 2μg/mL collagen induced PAR≥18ohm; AA†: 5*10^-3mg/mL arachidonic acid induced PAR>50%; AA§: 0.5g/L arachidonic acid induced PAR≥20%; ADP$: 1.0mmol/L adenosine diphosphate induced PAR≥70%; ADP¶: 110mmol/L adenosine diphosphate induced PAR≥70%.
Outcomes: ①ADP*18 ②AA*14 ③TXB2*5 ④COL*1 ⑤6-K-PGF1α*1 ⑥11-dTXB2*1 ⑦Clinical effective rate*2 ⑧CRP*1 ⑨hs-CRP*1 ⑩IL-6*1 ⑪NHISS score*1 ⑫BI score*1 ⑬Cerebral infarction reoccurrence rate*4 ⑭Acute myocardial infarction rate*1 ⑮Adverse events*7 ⑯hepar and renal function*1 ⑰Bleeding Events*5
ADP: PAR induced by adenosine diphosphate; AA: PAR induced by arachidonic acid; TXB2: thromboxane B2; COL: PAR induced by collagen; 6-K-PGF1α: 6-keto-prostaglandin F1α; 11-dTXB2: urinary 11-dehydro thromboxane B2; CRP: C response protein; hs-CRP: high-sensitivity C-reactive protein; IL-6: interleukin-6; NHISS: National Institutes of Health Stroke Scale; BI: Barthel Index.